NasdaqGS:BIIBBiotechs
RBC’s Confidence in Leqembi and MS Pipeline Might Change The Case For Investing In Biogen (BIIB)
Earlier this week, RBC Capital reaffirmed its positive view on Biogen, highlighting stabilization in the company’s core neurology franchise and growing expectations for Alzheimer’s therapy Leqembi, alongside the upcoming clinical trial start for multiple sclerosis candidate BIIB145.
The endorsement underscores how Biogen’s deep experience in neurological diseases may help it convert emerging Alzheimer’s demand and new MS research into a more resilient business mix over time.
We’ll now...